Trials / Completed
CompletedNCT00004581
A Study to Compare Two Anti-HIV Drug Combinations in HIV-Infected Patients Who Have Previously Received Anti-HIV Treatment
A Randomized, Open-Label, Phase III Study of ABT-378/Ritonavir in Combination With Nevirapine and Two Nucleoside Reverse Transcriptase Inhibitors (NRTIs) vs. Investigator Selected Protease Inhibitor(s) in Combination With Nevirapine and Two NRTIs in Antiretroviral-Experienced HIV-Infected Subjects
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 300 (planned)
- Sponsor
- Abbott · Industry
- Sex
- All
- Age
- 12 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to compare the safety and effectiveness of 2 anti-HIV drug combinations in HIV-infected patients. Both combinations will include nevirapine (NVP), 2 nucleoside reverse transcriptase inhibitors (NRTIs), and at least 1 protease inhibitor (PI). One combination will include a new protease inhibitor, ABT-378, combined in a capsule with ritonavir (RTV).
Detailed description
Patients receive 1 of the following: 1. ABT-378/RTV plus NVP plus 2 NRTIs; or 2. Investigator-selected PI(s) plus NVP plus 2 NRTIs.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lopinavir/Ritonavir | |
| DRUG | Nevirapine |
Timeline
- First posted
- 2001-08-31
- Last updated
- 2009-02-20
Locations
88 sites across 14 countries: United States, Australia, Austria, Brazil, Canada, Denmark, France, Germany, Poland, Puerto Rico, South Africa, Spain, Switzerland, United Kingdom
Source: ClinicalTrials.gov record NCT00004581. Inclusion in this directory is not an endorsement.